MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Perrigo Company plc Book Value 2011-2026 | PRGO
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.94 B | 4.32 B | 4.77 B | 4.84 B | 5.15 B | 5.66 B | 5.8 B | 5.67 B | 6.17 B | 5.96 B | 10.7 B | 8.69 B | 2.33 B | 1.85 B | 1.53 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.7 B | 1.53 B | 5.09 B |
Quarterly Book Value Perrigo Company plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.45 B | 4.47 B | 4.36 B | 4.32 B | 4.57 B | 4.55 B | 4.69 B | 4.77 B | 4.74 B | 4.85 B | 4.83 B | 4.84 B | 4.6 B | 4.85 B | 5.1 B | 5.15 B | 5.18 B | 5.51 B | 5.56 B | 5.66 B | 5.66 B | 5.66 B | 5.66 B | 5.8 B | 5.8 B | 5.8 B | 5.8 B | 5.67 B | 5.67 B | 5.67 B | 5.67 B | 6.17 B | 6.17 B | 6.17 B | 6.17 B | 5.96 B | 5.96 B | 5.96 B | 5.96 B | 10.1 B | 10.1 B | 10.1 B | 10.1 B | 9.72 B | 8.72 B | 8.72 B | 8.72 B | 13.7 B | 5.51 B | 10.7 B | 13.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.7 B | 13.1 M | 6.17 B |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.42 | 3.01 % | $ 86.3 M |  Canada |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 1.04 | 0.97 % | $ 24.3 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.71 B | $ 2.62 | 1.55 % | $ 1.39 B | Canada |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.21 | 2.43 % | $ 420 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.36 | -0.73 % | $ 3.37 M | Canada |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.28 | -2.56 % | $ 2.83 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.35 | 7.03 % | $ 47.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
-82 M | $ 5.08 | 1.8 % | $ 1.85 B | Canada |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
32.3 M | $ 2.29 | - | $ 309 M | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 23.49 | 1.25 % | $ 1.09 B | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 4.37 | -1.35 % | $ 282 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 7.23 | 8.23 % | $ 633 M | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 6.66 | 9.18 % | $ 263 M | USA |
 |
Tilray
TLRY
|
3.33 B | $ 6.94 | 4.2 % | $ 4.29 B | Canada |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.38 | 2.99 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 0.88 | -2.13 % | $ 43.9 M | USA |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 13.5 | 1.05 % | $ 16.2 B | USA |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 0.6 | 2.41 % | $ 10.5 M |  China |
 |
cbdMD
YCBD
|
1.96 M | $ 0.81 | 4.7 % | $ 3.49 M | USA |
 |
Assertio Holdings
ASRT
|
94 M | $ 18.57 | 12.48 % | $ 119 M | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 2.44 | 1.24 % | $ 321 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 0.97 | 1.5 % | $ 104 M | Canada |
 |
Harrow Health
HROW
|
52.1 M | $ 36.35 | 3.27 % | $ 1.34 B | USA |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 2.29 | - | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |